Cross-Sector entity

Respiratory Syncytial Virus (RSV) vaccine

Product
6

Respiratory Syncytial Virus (RSV) vaccine is most often covered alongside COVID-19 Vaccine, which appears in 3 of these 3 stories. The clearest coverage concentration is fda-approval: 1 of 3 stories, with the rest divided among 2 other categories. We currently track 3 Cross-Sector stories that mention Respiratory Syncytial Virus (RSV) vaccine, all published on July 21, 2026.

3 verified stories tracked

Last mentioned: Jul 21, 2026

RSS updates
Share

Entity pulse

Recent coverage · Respiratory Syncytial Virus (RSV) vaccine

3 stories
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Respiratory Syncytial Virus (RSV) vaccine

Respiratory Syncytial Virus (RSV) vaccine is most often covered alongside COVID-19 Vaccine, which appears in 3 of these 3 stories. The clearest coverage concentration is fda-approval: 1 of 3 stories, with the rest divided among 2 other categories. We currently track 3 Cross-Sector stories that mention Respiratory Syncytial Virus (RSV) vaccine, all published on July 21, 2026. Each carries 2 original sources on average.

Stories tracked
3
Sources per story
2

Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Respiratory Syncytial Virus (RSV) vaccine. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Cramer Endorsement & 109% YTD Gain

    Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.

  2. Quarterly Update

    Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.

  3. Post-Pandemic Decline

    Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.

  4. COVID Vaccine Success

    Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.

Stories mentioning Respiratory Syncytial Virus (RSV) vaccine 3